Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback